Phreesia, Inc. (PHR) AI Stock Analysis

Phreesia, Inc. is a healthcare software provider based in Raleigh, North Carolina. Founded in 2005, the company delivers its SaaS-based Phreesia Platform across the United States and Canada to streamline the patient intake workflow. The platform is accessed via Phreesia Mobile, web-based Phreesia Dashboard, self-service PhreesiaPads, and on-site Arrivals Kiosks. Its capabilities include automated patient self-registration, insurance verification, point-of-sale payment processing, and patient cost estimation. Phreesia also provides appointment scheduling, referral tracking, clinical intake, and patient-reported outcome data collection across approximately 25 medical specialties, along with patient communication tools such as surveys and health campaigns.

Phreesia expanded annual revenue from $213.2M in FY2022 to $480.6M in FY2026, delivering a 5-year revenue CAGR of 26.4%. Annual revenue growth moderated from 43.4% in FY2022 to 14.5% in FY2026. Gross margin expanded from 61.8% in FY2022 to 67.9% in FY2026. After recording net losses of -$118.2M in FY2022 and -$176.1M in FY2023, net income turned positive at $2.3M in FY2026, generating an EPS of $1.25. For the trailing twelve months ending July 31, 2026, revenue stood at $507.8M with an operating margin of 5.9% and EPS of $0.17. In the latest quarter, revenue grew 10.4% year-over-year while quarterly earnings grew 200.0%.

As of July 31, 2026, Phreesia held $72.9M in cash and short-term investments against total debt of $67.9M, resulting in net cash of $5.0M. Total assets were $647.0M against shareholders' equity of $371.9M. The company maintains a current ratio of 1.76 and a debt-to-equity ratio of 0.18. Operating cash flow improved to $78.8M in FY2026, yielding free cash flow of $67.7M after capital expenditures of $11.1M. Share issuance totaled $1.5M in FY2026, and the share count increased 22.4% over five years.

Phreesia trades at a trailing P/E of 64.4x, which is above the 24.6x median of its US-listed Healthcare peers. Its forward P/E of 12.0x sits below the peer median of 17.3x. Phreesia carries a price-to-sales multiple of 1.3x and an EV-to-EBITDA multiple of 11.9x, compared to peer medians of 4.1x and 12.0x, respectively. The stock closed at $10.94 on October 16, 2026, having declined 51.9% over the past year compared to a 16.8% gain for the S&P 500 (SPY). Over five years, the stock dropped 82.8% while the S&P 500 gained 83.0%.

Wall Street coverage includes 8 Strong Buy, 2 Buy, and 8 Hold ratings, with no Sell or Strong Sell recommendations. The mean price target is $14.13, which is 29.2% above the last close of $10.94. For the fiscal year ending January 31, 2027, consensus estimates project revenue of $515.8M and an EPS of $1.28, reflecting an EPS growth estimate of -1.0%. For the following fiscal year, 9 analysts project revenue of $534.9M and EPS of $1.61. Over the last four quarters, Phreesia beat EPS estimates 2 times.

This page is an AI-written research summary of Phreesia, Inc. (PHR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: PHR income statement, PHR balance sheet, PHR key metrics, PHR analyst forecast, PHR chart. See the PHR stock overview for the latest quote and news.